Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 79

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Comparison of Efficacy, Safety, and Tolerability of On-Demand Tadalafil and Daily Dosed Tadalafil for the Treatment of Erectile Dysfunction

McMahon, Chris·2005·The Journal of Sexual Medicine
DOI 10.1111/j.1743-6109.2005.20360.x
Open this paper in CoChat — free account

Abstract

Objective: To assess and compare the efficacy of on-demand tadalafil and daily tadalafil in the treatment of erectile dysfunction. Materials and Methods: A total of 145 men with a mean age of 57.3 years (range 19–82 years) and mild to severe erectile dysfunction of various etiologies were randomized to receive on-demand tadalafil (20 mg) or daily tadalafil (10 mg) taken without food or alcohol restrictions in a trial lasting 26 weeks. The three primary outcome measures were changes from baseline in the erectile function domain of the International Index of Erectile Function (IIEF), the proportion of “yes” responses to questions 2 and 3 of the Sexual Encounter Profile (SEP). Additional efficacy instruments included a Global Assessment Question administered at completion of the study. Results: Compared with baseline, on-demand and daily tadalafil enhanced all efficacy outcomes. Patients receiving on-demand tadalafil (20 mg) and daily tadalafil (10 mg) experienced a significant mean improvement of 8.3 and 11.9, respectively, in the erectile function domain of the IIEF from baseline (P < 0.001). The mean change from baseline was significantly higher for daily dosed tadalafil than for on-demand tadalafil (P < 0.05). Sexual intercourse was successfully completed (SEP3) in 69% and 84% of patients taking on-demand tadalafil and daily tadalafil, respectively, compared with 30% at baseline (P < 0.001). Successful completion of sexual intercourse was statistically higher for daily tadalafil than for on-demand tadalafil (P < 0.05). Treatment with on-demand tadalafil or daily tadalafil was well tolerated, and headaches, facial flushing, and dyspepsia were the most frequently observed adverse events. Conclusion: Tadalafil was effective and well tolerated in this patient population. Treatment with daily tadalafil was associated with a significantly higher IIEF erectile function domain score and completion of successful intercourse compared with on-demand tadalafil.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1743-6109.2005.20360.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 34

  1. Kloner, 2003, Cardiovascular effects of tadalafil, Am J Cardiol, 92, 37, 10.1016/S0002-9149(03)00074-2 · DOI · Paper page
  2. Jackson, 2004, Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events, J Sex Med, 1, 161, 10.1111/j.1743-6109.2004.04024.x · DOI
  3. Azadzoi, 1991, Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle, J Urol, 146, 238, 10.1016/S0022-5347(17)37759-5 · DOI
  4. Azadzoi, 1992, Erectile dysfunction due to atherosclerotic vascular disease: The development of an animal model, J Urol, 147, 1675, 10.1016/S0022-5347(17)37676-0 · DOI
  5. Saenz de Tejada, 1989, Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence, N Engl J Med, 320, 1025, 10.1056/NEJM198904203201601 · DOI
  6. Virag, 1985, Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men, Lancet, 1, 181, 10.1016/S0140-6736(85)92023-9 · DOI · Paper page
  7. Jensen, 1999, The prevalence and etiology of impotence in 101 male hypertensive outpatients, Am J Hypertens, 12, 271, 10.1016/S0895-7061(98)00225-8 · DOI
  8. Kaiser, 2004, Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease, J Am Coll Cardiol, 43, 179, 10.1016/j.jacc.2003.07.042 · DOI
  9. Brock, 2002, Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses, J Urol, 168, 1332, 10.1016/S0022-5347(05)64442-4 · DOI · Paper page
  10. Porst, 2003, Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial, Urology, 62, 121, 10.1016/S0090-4295(03)00359-5 · DOI · Paper page
  11. Eli Lilly Corporation., Cialis®; (tadalafil HCI) tablets: prescribing information
  12. Anderson, 1991, Cardiovascular disease risk profiles, Am Heart J, 121, 293, 10.1016/0002-8703(91)90861-B · DOI · Paper page
  13. Montorsi, 2004, Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction, Eur Urol, 45, 339, 10.1016/j.eururo.2003.11.010 · DOI
  14. Kloner, 2003, Cardiovascular effects of tadalafil, Am J Cardiol, 92, 37, 10.1016/S0002-9149(03)00074-2 · DOI · Paper page
  15. Saenz de Tejada, 2002, Effects of tadalafil on erectile dysfunction in men with diabetes, Diabetes Care, 25, 2159, 10.2337/diacare.25.12.2159 · DOI · Paper page
  16. Rendell, 1999, Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial, JAMA, 281, 421, 10.1001/jama.281.5.421 · DOI
  17. Goldstein, 2003, Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study, Diabetes Care, 26, 777, 10.2337/diacare.26.3.777 · DOI
  18. Emmick, 2002, Overview of the cardiovascular effects of tadalafil, Eur Heart J, 4, 32, 10.1016/S1520-765X(02)90050-7 · DOI
  19. DeHoll, 1998, Alternative approaches to the management of priapism, Int J Impot Res, 10, 11, 10.1038/sj.ijir.3900308 · DOI
  20. Brock, 2003, Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy, J Urol, 170, 1278, 10.1097/01.ju.0000086947.00547.49 · DOI
  21. Hong, 1999, Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP), Int J Impot Res, 11, S15, 10.1038/sj.ijir.3900466 · DOI
  22. Montorsi, 1997, Recovery of spontaneous erectile function after nerve sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective, randomized trial, J Urol, 158, 1408, 10.1016/S0022-5347(01)64227-7 · DOI · Paper page
  23. Levine, 2004, Longitudinal randomized placebo-controlled study of the return of nocturnal erections after nerve-sparing radical prostatectomy in men treated with nightly sildenafil citrate, J Urol, 171, 231, 10.1016/S0022-5347(18)38124-2 · DOI
  24. El-Galley, 2001, Long-term efficacy of sildenafil and tachyphylaxis effect, J Urol, 166, 927, 10.1016/S0022-5347(05)65866-1 · DOI
  25. Steers, 2001, Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment, Int J Impot Res, 13, 261, 10.1038/sj.ijir.3900714 · DOI
  26. Lin, 2002, Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters, Int J Impot Res, 14, 15, 10.1038/sj.ijir.3900802 · DOI
  27. Gonzalez, 1999, Sildenafil causes a dose- and time-dependent downregulation of phosphodiesterase type 6 expression in the rat retina, Int J Impot Res, 11, S9, 10.1038/sj.ijir.3900465 · DOI
  28. Lin, 2003, Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism, J Urol, 170, S15
  29. Ferrini, 2004, Long-term treatment with high doses of sildenafil does not up-regulate the levels of phosphodiesterase 5 (PDE5) in the rat penis, J Urol, 171, 424, 10.1016/S0022-5347(18)38816-5 · DOI
  30. Behr-Roussel, 2005, Chronic sildenafil enhances erectile responses and endothelium-dependent corporal relaxations of normal rats: Lack of tachyphylaxis, Eur Urol, 47, 87, 10.1016/j.eururo.2004.09.005 · DOI
  31. Halcox, 2002, The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia, J Am Coll Cardiol, 40, 1232, 10.1016/S0735-1097(02)02139-3 · DOI · Paper page
  32. Desouza, 2002, Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes, Diabetes Care, 25, 1336, 10.2337/diacare.25.8.1336 · DOI
  33. Kimura, 2003, PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers, Hypertension, 41, 1106, 10.1161/01.HYP.0000068202.42431.CC · DOI
  34. Katz, 2000, Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure, J Am Coll Cardiol, 36, 845, 10.1016/S0735-1097(00)00790-7 · DOI · Paper page

Cited by

See all 79

Metadata

Authors
McMahon, C.
Affiliations
Australian Centre for Sexual Health , Sydney, NSW , Australia
Venue
The Journal of Sexual Medicine
Publisher
Oxford University Press (OUP)
Published
2005-05-01
Volume
2
Issue
3
Pages
415-427
ISSN
  • 1743-6109
  • 1743-6095
DOI
10.1111/j.1743-6109.2005.20360.x
Cited by
79
References
1
Language
en
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.